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Background: Human endogenous retroviruses (HERVs) are remnants of ancestral infections and chromosomally
integrated in all cells of an individual, are transmitted only vertically and are defective in viral replication. However
enhanced expression of HERV-K accompanied by the emergence of anti-HERV-K-directed immune responses has
been observed inter-alia in HIV-infected individuals and tumor patients. Therefore HERV-K might serve as a
tumor-specific antigen or even as a constant target for the development of an HIV vaccine.
Results: To verify our hypothesis, we tested the immunogenicity of HERV-K Gag by using a recombinant vaccinia
virus (MVA-HKcon) expressing the HERV-K Gag protein and established an animal model to test its vaccination
efficacy. Murine renal carcinoma cells (Renca) were genetically altered to express E. coli beta-galactosidase
(RLZ cells) and the HERV-K Gag protein (RLZ-HKGag cells). Subcutaneous application of RLZ-HKGag cells into
syngenic BALB/c mice resulted in the formation of local tumors in MVA vaccinated mice. MVA-HKcon vaccination
reduced the tumor growth. Furthermore, intravenous injection of RLZ-HKGag cells led to the formation of
pulmonary metastases. Vaccination of tumor-bearing mice with MVA-HKcon drastically reduced the number of
pulmonary RLZ-HKGag tumor nodules compared to vaccination with wild-type MVA.
Conclusion: The data demonstrate that HERV-K Gag is a useful target for vaccine development and might offer
new treatment opportunities for cancer patients.
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HERVs are relics of ancient viral infections events into
the germ line and are since then transmitted vertically.
These retrovirus genomes are chromosomally integrated
in all cells of an individual and their sequences comprise
about 8% of the human genome. HERVs are historically
classified by the single letter amino acid code for the
tRNA specific of the primer binding site used to initiate
reverse transcription. Integrated endogenous retrovirus
genomes commonly contain mutations, deletions or are
reduced to a single LTR element, and so have mainly
lost the ability to be transferred. In contrast, HERV-K is* Correspondence: schba@pei.de
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unless otherwise stated.the only known endogenous retrovirus encoding all
structural and enzymatic proteins (Gag, Prt, Pol), as well
as an envelope protein (Env) and an accessory protein
Rec with functional similarity to the HIV Rev protein.
Despite this, HERV-K is not infectious and its gene ex-
pression is generally repressed. However, reactivation of
HERV-K proviruses coding for all viral proteins occurs
under certain circumstances and is well established for
human teratocarcinomas [1], melanomas [2] and ovarian
cancer [3,4]. The overexpression of Gag has been seen in
the peripheral blood cells of leukemia patients [5] and
also in prostate cancer and ovarian cancer but not in
healthy donors [6,7].
Tumor-associated antigens (TAAs), proteins expressed
mainly or exclusively by tumor cells, can be used fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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of minimal residual disease. The induction of immuno-
logical memory may even prevent disease relapse. Re-
combinant poxviruses are frequently used as vaccine
vectors, because they activate robust cellular MHC class I-
and II-restricted CD8+ and CD4+ T cell responses against
recombinant antigens [8].
Here we tested a recombinant vaccinia virus express-
ing the HERV-K Gag gene for its efficacy in elucidating
a cytotoxic immune response, which might be beneficial
as a novel cancer vaccine.
Results
Establishment of an animal model and the experimental
vaccine
The development of HERV-K-specific vaccines is ham-
pered by the availability of an appropriate animal model
because HERV-K is exclusively expressed in humans. To
bypass this limiting fact, we previously have generated a
syngeneic mouse model for HERV-K Env [9] and ex-
panded this model to HERV-K Gag. Murine renal car-
cinoma cells (Renca) were genetically altered to express
E. coli beta-galactosidase (RLZ cells) [10] and the HERV-
K Gag gene was introduced by retroviral transduction
(RLZ-HKGag cells). The engineered cell line RLZ-HKGag
is positive for Gag expression, as illustrated by a puncturedRLZ-HKGag
RLZ
-HERV-K GAG -HERV-K GAG + DAPIA B
C
Figure 1 Characterization of RLZ-HKGag cells and MVA-HKcon. A: Imm
and stained either with an anti-HERV-K Gag antibody alone or in combinat
was analyzed by flow cytometry either with an antibody directed against H
used as negative control. C: Western Blot analysis of MVA-HKcon-infected 293
lysates were prepared at the indicated time points. HERV-K GAG was id
chemiluminescent detection. Detection of ß-actin was used as loadingpositive staining shown by immunofluorescence analysis
(Figure 1A upper left panel). To confirm that Gag expres-
sion is not silenced during cell propagation, we passaged
the cells in vitro and in vivo and investigated cell lysates
for Gag expression by Western blot analysis. The cells
could be passaged without silencing of Gag expression
in vitro and in vivo (data not shown). Both cell lines (RLZ
and RLZ-HKGag) expressed MHC class I at similar levels
(Figure 1B). Subcutaneous application of RLZ-HKGag cells
into syngeneic BALB/c mice resulted in local tumors and
intravenous application of cells gave rise to pulmonary
metastases, which were detectable by X-gal staining upon
excision of the lungs (data not shown).
As a vaccine vector, we chose the modified vaccinia
virus Ankara (MVA). MVA is a highly attenuated and
replication-deficient strain of vaccina virus that has been
demonstrated to be safe for humans and is widely and
increasingly considered as the vaccinia virus strain of
choice for clinical investigation because of its excellent
safety profile. Despite its inability to replicate in most
mammalian cells, MVA still efficiently expresses viral and
recombinant genes making it a potent antigen delivery
platform. We inserted the coding sequence of HERV-K
gag into the MVA genome via homologous recombination
[11]. The recombinant MVA (MVA-HKcon; named after
the consensus gene) encodes the consensus HERV-K Gag-RLZ
RLZ-HKGag
293-T












un-fluorescence analysis of RLZ and RLZ-HKGag cells. Cells were fixed
ion with DAPI. B: MHC class I expression MHC class I (H2Kd) expression
2Kd or a control antibody of the same isotype. Human 293 T cells were
T cells 293 T cells were infected at an MOI of 5 with MVA-HKcon and cell
entified with the HERV-K GAG monoclonal antibody followed by
control.
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moter (mH5). MVA gene expression is cascade like and
the use of synthetic promoters that combine early and late
elements is well established to maximize transgene ex-
pression [13]. Infection of 293 T cells at an MOI of 5
showed a typical early/late expression pattern of HERV-K
Gag with high amounts of the precursor protein (90 kDa)
and processed GAG proteins (50 and 30 kDa) (Figure 1C).
In addition, we were able to show that infected cells
produce virus-like HERV-K particles that bud from
the cells [11].
Vaccination with MVA-HKcon delays the tumor growth of
subcutaneous tumors
In addition to be used as a tumor specific antigen,
HERV-K Gag might be used as a novel HIV vaccine. In
contrast to the rapidly mutating HIV-1 genome, HERVs
are cellular genes that are not prone to mutation. HERV-
K gene products are described to be overexpressed in
HIV-infected individuals, and T-cell responses that are ef-
fective in lowering the HIV-1 viral load are potential
therapeutic vaccine targets. So it is envisioned that a vac-
cine directed against HERV-K might also be valuable for
the treatment of HIV-infected patients [14,15].
We tested the experimental vaccine in a therapeutic
setting by starting with the subcutaneous injection of
1x106 RLZ HKGag cells into the flanks of BALB/c mice
on day 0. Ten days later, after the cells were able to form
palpable tumors, the mice were vaccinated intramuscu-
larly with either MVA-HKcon or MVA (10
8 IU/mouse;
n = 10). The initial tumor volume was similar in all
mice and was monitored by caliper measurements. Out
of ten mice, six mice in the MVA-vaccinated control
group developed tumors. However, after MVA-HKcon vac-
cination, only two mice had papable tumors that were sig-
nificantly smaller on day 18 after transplantation than
those of MVA-vaccinated mice (Figure 2). Although













Figure 2 Specificity of the vaccination in a subcutaneous tumor mod
with 106 RLZ-HKGag cells and immunized with either 108 IU/mouse MVA-H
by caliper measurements. The arrow indicates the vaccination on day 10.show unconvincing statistically significant differences
(p = 0.044), it nonetheless suggested that HERV-K GAG
directed immune responses were generated and able to
constrain tumor growth.
Vaccination with MVA-HKcon reduces the number of lung
metastases
We validated the above data in a second experiment
using the systemic application of Renca cells which leads
to the formation of lung metastasis instead of subcuta-
neous tumors. Therefore, 1 × 106 RLZ-HKGag cells were
applied intravenously into the tail vein of BALB/c mice.
The application of cells was defined as day 0 of the
experiment. Ten days later, after the cells have had
the chance to colonize the lung, the mice were vacci-
nated intramuscularly with either MVA-HKcon or MVA
(107 IU/mouse; n = 7) (Figure 3). The vaccination was re-
peated on day 17 (107 IU/mouse). On day 33, mice
were sacrificed and the lungs were excised, fixed and
stained for beta-galactosidase. In five out of seven
MVA-HKcon-vaccinated animals only one stainable me-
tastasis could be found. Two animals were completely me-
tastasis free (Figure 3). On the contrary MVA-vaccinated
animals had a much higher tumor burden. Except for one
mouse, all mice developed lung metastasis as quanti-
fied in Figure 3. Statistical analysis shows that there
was a statistically significant difference in the number
of metastases with a p-value of 0.031 (Figure 3). In sum-
mary, vaccination with MVA-HKcon severely decreased
the outgrowth of pulmonary tumors.
Discussion
Here, we assessed an experimental vaccine candidate for
its efficacy to eliminate autologous HERV-K positive
cells in vivo. We chose a vaccine candidate known to
elicit strong T cell responses in vivo. The vaccine candi-
date is based on the modified vaccinia virus Ankara
(MVA), a highly attenuated vaccinia virus strain with aMVA HKcon
el. Two groups of BALB/c mice (n = 10) were injected subcutaneously
Kcon or 10






























Figure 3 Specificity of the vaccination in a lung metastasis tumor model. Two groups of BALB/c mice (n = 7) were injected i.v. with 106
RLZ-HKGag cells and immunized with 107 IU/mouse MVA-HKcon or MVA i.m. on day 10 and 17. The animals were sacrificed on day 33, lungs were
removed, and stained with X-Gal. The number of tumor nodules was counted on the surface of the lungs. Data for each mouse are shown. The
p-value of 0.0313 shows significance.
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munosuppressed patients [16,17]. MVA does not repli-
cate in human cells but shows high protein expression
and, consequently, has a very good safety profile without
compromising vaccination efficiency. As shown before,
MVA vaccination generates antigen specific cellular im-
munity that is believed to be responsible to clear antigen
expressing cells [9].
Vaccine efficacy testing of the recombinant MVA-
HKcon was performed in a surrogate mouse model, using
a syngeneic mouse tumor cell line which was genetically
engineered to express HERV-K Gag. Since HERV-K ex-
pression is normally repressed in humans, it is expected
that humans are not tolerant to HERV-K gene products
and so our simplistic animal model might be appropriate
as well. Vaccinations were performed in a therapeutic
setting after the establishment of tumor nodules in the
mice testing two tumor application routes. Subcutaneous
tumor growth and the formation of pulmonary metasta-
sis in the mice after i.v. application were significantly re-
duced. These data indicate a therapeutic effect of the
HERV-K GAG-directed vaccination.
Two therapeutic applications can be envisioned for
this vaccine candidate. First, as described before for a
HERV-K Env expressing MVA, MVA-HKcon could be used
as a tumor vaccine [9]. However, in addition HERV-K Gagmight be used as a surrogate target to develop an HIV
vaccine. Despite significant progress and several clinical
trials, a safe and effective AIDS vaccine is still elusive. The
virus evolved unique ways of evading the immune system,
and the human body seems to be incapable of mounting
an effective immune response against it. The retrovirus
HIV is hypervariable due to its high mutation rate and
the ability to recombine; for vaccine development this
means aiming at a moving target. Recently, several re-
ports indicate that HERV-K is activated by HIV infection
(see review by van der Kuyl [18] and cell-mediated im-
mune responses directed against HERV-K are effective in
lowering HIV-1 viral loads and correlated with control of
HIV-1 viremia [14,15,19]. In addition, antibodies directed
against HERV-K were detected in 70 to 80% of patients
with HIV viremia. In contrast, only 2% of normal healthy
controls were tested anti-HERV-K positive [20]. Then
again the absence of HERV-specific antibodies in AIDS
patients has been reported as well [21-23].
A direct link between HERV-K activation and HIV in-
fection was suggested recently [24]. Gonzalez-Hernandez
and colleagues reported that addition of recombinant
HIV-1 Tat protein to Jurkat cells caused a 13-fold increase
in HERV-K gag RNA transcripts and a 10-fold increase in
treated primary lymphocytes [24]. However, the correl-
ation between HIV infection and HERV-K expression is
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pression in HIV-infected cells from patients are not yet
available and expression of HERV-K in CD8+ cells cannot
be excluded [25]. In addition, HERV-K pol expression
has been described after herpes virus, hepatitis B and
C virus infections [18], indicating a more general mech-
anism of activation. Quantification of HERV-K RNA in
HIV-infected patients under HAART showed a correl-
ation of HERV-K and HIV viral load, however an effect
of HAART on HERV-K cannot be excluded [26]. In gen-
eral, no significant correlation has been described between
HIV viral load, CD4+ T cell counts and HERV-K protein
titers [18].
In contrast, Garrison et al. [19] demonstrated the stimu-
lation of HERV-specific T cell responses in HIV-positive
participants by ELISPOT detection [19]. Interestingly,
HERV-specific T-cell responses inversely correlated with
HIV-1 plasma viral load [19]. Another study showed that
HIV infected individuals (Long-term nonprogressors
(LTNPs) or elite controllers), who control HIV-1 viremia
without highly active antiretroviral therapy (HAART) had
stronger and broader HERV-specific T cell responses than
HAART-suppressed patients, virologic noncontrollers,
immunologic progressors, and uninfected controls. In
addition, the magnitude of the anti-HERV Tcell response
inversely correlated with HIV-1 viral load and associated
with higher CD4 T cell counts in untreated patients. This
suggests a beneficial effect of anti-HERV immunity in the
control of chronic HIV-1 infection [14]. Moreover, a
HERV-K–specific CD8+ T cell clone has been described
to be able to eliminate cells infected with a panel of glo-
bally diverse HIV-1, HIV-2, and SIV isolates in vitro, indi-
cating that HERV-K–specific T cell responses might be
involved in the control of HIV-1 infections [15].
Although still discussed controversially, a lot of data
indicate that HIV-1 infection leads to the expression of
otherwise repressed HERV-K and consequently to the
stimulation of HERV-specific immune responses which
in turns might help to control the HIV infection. How-
ever, still basic issues need to be clarified. Are HERV-K
epitopes expressed significantly and exclusively in HIV-
infected cells; T cells as well as monocytes. Another
open issue is the next step towards clinical development.
Side effects of an HERV-K-specific vaccination can only
be studied in humans.
Recent observations of HERV-K expression in embry-
onic and induced pluripotent stem cells [27] might also
be of concern, however embryonic stem cells are located
in an immune protected tissue and should not be recog-
nized by HERV-K-specific immune responses. However,
potential hazardous HERK-K expression in hematopoietic
stem cells still needs to be analyzed. Primates encode very
similar endogenous retroviral genomes (SERV) and could
be used as a model for safety studies [28-31]. Vaccinationof rhesus macaques which carry SERV-K with SERV-K
Gag or Env induced T cell responses without vaccine-
related pathogenicity [31].
HERV-K Env expression has also been observed in di-
verse types of human tumors. We recently showed proof
of principle that vaccination directed against the HERV-K
envelope protein had anti-tumor activity [9]. A HERV-K
Gag directed vaccine might therefore be used as a tumor
vaccine and might have in addition an application as a
HIV vaccine.
Methods
Cell culture and virus
HEK 293 T (ATCC: CRL-1573) and Renca (CRL-2947)
cells were cultured in complete Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine
serum, penicillin (50 U/ml), streptomycin (50 μg/ml),
Zeocin (RLZ cells; 50 μg/ml) and L-glutamine (2 mM),
and propagated by standard techniques. For the gener-
ation of the RLZ-HKGag cell line, MLV-based retroviral
vectors were produced encoding a codon-optimized
HERV-K GAG gene via the pBabe-puro vector. For se-
lection of transduced cells, 1 μg/ml puromycin was
added to the RLZ-HKGag medium.
The recombinant virus MVA-HERV-Kcon was gener-
ated as described before [11].
Western blot
Western blot was performed with a BIO-Rad semi-dry
blotter. Proteins separated by SDS-PAGE were blotted
onto PVDF membranes with 50 mM sodium borate
pH 9.0, 20% methanol, and 0.1% SDS at 100 mA per
membrane for 75 min. Afterwards, membranes were
blocked with Roti-Block™ and proteins were detected
with α-HERV-K capsid monoclonal antibodies [32] and
the ECL detection system (Amersham, Freiburg).
Immunofluorescence staining of cells
Cells were fixed with 2% paraformaldehyde and HERV-K
Gag was detected after successive incubations with
α-HERV-K capsid monoclonal antibodies [32] and a
FITC-coupled goat anti-mouse IgG antibody (DAKO,
Hamburg, Germany). Additionally cells were stained with
DAPI. Cells were examined with a 400× magnification.
Flow cytometry
Cells were incubated with the indicated antibodies for
60 min at 4°C at the appropriate dilution as determined
by previous titration. Cells were washed with FACS
buffer and analyzed by flow cytometry. At least 10.000
events were acquired with an LSRII instrument (BD
Biosciences) and analyzed using FACS Diva Software.
Matching isotype control antibodies were used as negative
controls.
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Female specific pathogen-free 6–8-week-old BALB/c
mice were purchased from Harlan. For tumor transplan-
tations, RLZ-HKGag cells were grown to 60–80% con-
fluence and detached from the culture dish via trypsin
digestion. Cells were washed three times with PBS and
resuspended in PBS at a density of 1 × 106 cells/100 μl
for vaccination experiments. Indicated cell numbers
were injected subcutaneously into the flanks or i.v. into
the tail vein of mice using standard techniques. Mice
were immunized with the indicated amounts of recom-
binant MVA intra-muscularly into the quadriceps mus-
cles of the hind limbs and then weighed every 3 days.
Mice were sacrificed at the indicated time points, and
the lungs were prepared and incubated in fixing solution
(0.2% glutaraldehyde, 2% formaldehyde in PBS) over-
night at 4°C. For X-Gal staining, lungs were incubated in
staining solution (5 mM potassium ferrocyanide, 5 mM
potassium ferricyanid, 1 mM MgCl2, 1 mg/ml X-Gal in
PBS) for 24 h. Stained lungs were stored in PBS contain-
ing 4% formaldehyde and metastases were counted. All
experiments were performed in accordance to legal re-
quirements (Regional Council Darmstadt).
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